ArticleBMC medicine2025
Trend analysis and future predictions of global burden of alzheimer's disease and other dementias: a study based on the global burden of disease database from 1990 to 2021.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Virtual reality-based training in patients with alzheimer's disease: A systematic review and meta-analysis.The journal of prevention of Alzheimer's disease · 2026Pooled it
- Effectiveness of eHealth Interventions in Alleviating Burden on Informal Caregivers of People With Dementia: Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of medical Internet research · 2026Pooled it
- The Role of Antidiabetic Therapies in Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review of Metformin, Pioglitazone, and GLP-1 Receptor Agonists.International journal of molecular sciences · 2026Pooled it
- Digital technology-based dyadic interventions in patients with mild cognitive impairment or dementia and their caregivers: a scoping review.Frontiers in psychiatry · 2026Pooled it
- Associations of long-term exposure to source-specific PMEuropean archives of psychiatry and clinical neuroscience · 2026Article
- Trends in Population-Level Mortality Rates for Deaths With Both Alzheimer's Disease and Cancer Recorded on Death Certificates Among U.S. Adults Aged ≥ 65 Years, 1999-2023.Nursing open · 2026Article
- Neuropathological diagnoses and age-related differences in Finnish medico-legal autopsies of individuals aged 65 years and older.Forensic science, medicine, and pathology · 2026Article
- The Burden of Alzheimer's Disease and Other Dementias Attribute to Metabolic Risks in Western Europe From 1990 to 2023.Diabetes, obesity & metabolism · 2026Article
- The growing burden of dementia in Asia: Comparative insights from Japan, China, and India.The journal of prevention of Alzheimer's disease · 2026Article
- Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer's disease.Ageing research reviews · 2026Review
- 2-(Arylamino)thiazol-4(5H)-ones Mitigate Oxidative Stress and Confer Neuroprotection in Cellular andInternational journal of molecular sciences · 2026Article
- Phytochemicals in Alzheimer's Disease Prevention and Management: Molecular Mechanisms, Therapeutic Potential, Translational Challenges, and Emerging Research Directions.International journal of molecular sciences · 2026Review
- Association between continuous metabolic syndrome score and incident dementia: a longitudinal study of middle-aged and older Chinese adults.BMC neurology · 2026Article
- Article
- The Relationship Between Voluntary Rapid Blinking Rate and Future Development of Neurodegenerative Disease.Geriatrics & gerontology international · 2026Article
- Polyphenols Suppress Intracellular Zinc Deficiency-Induced ROS Production and NLRP3 Inflammasome Activation in Microglial and Neuronal Cells.Biomolecules · 2026Article
- Dual trajectories of intrinsic capacity and frailty: a joint predictor framework for dementia risk in middle-aged and older adults.BMC public health · 2026Article
- Dementia transition in early cognitive decline trajectories (DETECT) study: a prospective longitudinal study protocol.BMC geriatrics · 2026Article
- Sensory impairment and cognitive impairment among older adults in rural China: personal responsibility for health as a possible moderator?BMC geriatrics · 2026Article
- Cellular Senescence of Patient-derived Fibroblasts Reveals the Mid-old Stage as a Critical Window for Transcriptomic Signatures Linked to Alzheimer's Disease Biomarkers and Classification.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundAs the global aging issue grows, dementia, particularly Alzheimer's disease (AD), has become a major public health challenge for everyone. This study utilizes the Global Burden of Disease (GBD) database to analyze trends in the epidemiology of AD and other dementias from 1990 to 2021 and to predict future burdens to 2040.
methodsWe examined global, regional, and national data on AD and other dementias, focusing on incidence, prevalence, and Disability-Adjusted Life Years (DALYs). Joinpoint regression analysis was employed to identify significant changes in trends over time. The effects of age, period, and birth cohort on the risk of AD and other dementias were analyzed. Additionally, the impact of aging, population growth, and epidemiological changes on DALYs was assessed across different Socio-demographic Index (SDI) quintiles.
resultsThe global burden of AD and other dementias has significantly increased, with the highest incidence, prevalence, and DALYs observed in East Asia. A notable increase in prevalence was observed in females over 65 years compared to males. Joinpoint regression analysis revealed substantial changes in trends in 1995, 2005, 2011, and 2019, with a noticeable acceleration post-2011, especially after 2019. Age was a significant risk factor, with a sharp increase in risk after 60 years of age. Epidemiological changes had a minor impact globally but varied by region and gender. Bayesian age-period-cohort modeling predicts sustained growth through 2040, with age-standardized incidence and prevalence rates projected to reach 144.85 and 821.80 per 100,000 respectively, driven predominantly by aging populations in high SDI regions and demographic expansion in low SDI regions.
conclusionsThe global burden of AD and other dementias is escalating, with a pronounced increase expected by 2040. This study highlights the need for targeted interventions, particularly in regions with higher burdens and among older populations. The findings underscore the importance of considering SDI, age, and gender when planning public health strategies to address the growing challenge of AD and other dementias.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.